Press releases

European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease

January 27, 2023 - Regulatory press release

Stockholm, January 27, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing ...

Invitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET

January 25, 2023 - Other press release

Stockholm, Sweden, January 25, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s fourth quarter report for October – December 2022 on ...

BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election

January 19, 2023 - Regulatory press release

Stockholm, January 19, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Chairman of the Board of Directors, Wenche Rolfsen, has informed the Nomination Committee that ...

BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in Japan

January 16, 2023 - Regulatory press release

Stockholm, January 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab ...

BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in the EU

January 11, 2023 - Regulatory press release

Stockholm, January 11, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application (MAA) for ...

BioArctic’s partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease

January 7, 2023 - Other press release

Stockholm, January 7, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today they have submitted a supplemental Biologics License Application (sBLA) to ...

FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer’s disease

January 6, 2023 - Regulatory press release

Stockholm, January 6, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and ...

BioArctic moves to Nasdaq Stockholm Large Cap

January 2, 2023 - Other press release

Stockholm, January 2, 2023 – As of today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will move to the Large Cap listing on the Nasdaq Stockholm ...